Loading
A phase 3 trial testing DZD8586 in chronic lymphocytic leukaemia, now recruiting.
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) is a phase 3 interventional study registered as NCT07139873, led by Dizal Pharmaceuticals, and recruiting on the registry. Official title: A Phase 3, Open-Label, Randomised, Multicenter Study to Evaluate Anti-tumour Efficacy of DZD8586 Versus Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma. Planned enrolment is 250 participants (estimated). The study started in 2025-09-08 and primary completion is expected in 2029-01. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares DZD8586, Dizal Pharmaceutical, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares DZD8586, Dizal Pharmaceutical, Chronic lymphocytic leukaemia.
Shares DZD8586, Dizal Pharmaceutical.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/